AstraZeneca's Lynparza approved in China for prostate cancer

Retrieved on: 2021-06-24 06:22:30

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca's Lynparza approved in China for prostate cancer. View article details on hiswai:

Excerpt

AstraZeneca plc (LON:AZN) and MSD's Lynparza (olaparib) has been granted conditional approval in China to treat adult patients with germline or ...

Article found on: www.directorstalkinterviews.com